+

AR061136A1 - Procedimiento - Google Patents

Procedimiento

Info

Publication number
AR061136A1
AR061136A1 ARP070102352A ARP070102352A AR061136A1 AR 061136 A1 AR061136 A1 AR 061136A1 AR P070102352 A ARP070102352 A AR P070102352A AR P070102352 A ARP070102352 A AR P070102352A AR 061136 A1 AR061136 A1 AR 061136A1
Authority
AR
Argentina
Prior art keywords
gene expression
refers
expression profiles
microdispositions
tumors
Prior art date
Application number
ARP070102352A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0610949A external-priority patent/GB0610949D0/en
Priority claimed from GB0700761A external-priority patent/GB0700761D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR061136A1 publication Critical patent/AR061136A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente se refiere a perfiles de expresion de genes, microdisposiciones que comprenden secuencias de ácido nucleico que representan perfiles de expresion de genes y nuevos kits y procedimientos de diagnostico. La presente además se refiere al tratamiento de poblaciones específicas de, por ejemplo, pacientes de cáncer, como se caracteriza por su perfil de expresion génica, que padecen tumores que expresan Mage.
ARP070102352A 2006-06-02 2007-05-31 Procedimiento AR061136A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0610949A GB0610949D0 (en) 2006-06-02 2006-06-02 Method
GB0700761A GB0700761D0 (en) 2007-01-15 2007-01-15 Method

Publications (1)

Publication Number Publication Date
AR061136A1 true AR061136A1 (es) 2008-08-06

Family

ID=38801855

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102352A AR061136A1 (es) 2006-06-02 2007-05-31 Procedimiento

Country Status (15)

Country Link
US (1) US20100021424A1 (es)
EP (23) EP2392672A1 (es)
JP (1) JP2009538607A (es)
KR (1) KR20090017655A (es)
AR (1) AR061136A1 (es)
AU (1) AU2007256383B2 (es)
BR (1) BRPI0712497A2 (es)
CA (1) CA2653949A1 (es)
CL (1) CL2007001571A1 (es)
EA (1) EA200802242A1 (es)
ES (1) ES2539042T3 (es)
MX (1) MX2008015372A (es)
PE (1) PE20080742A1 (es)
TW (1) TW200817680A (es)
WO (1) WO2007140958A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
GB0816867D0 (en) * 2008-09-15 2008-10-22 Glaxosmithkline Biolog Sa Method
GB2466025A (en) * 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
WO2011084333A1 (en) * 2009-12-16 2011-07-14 Hitachi Chemical Co., Ltd. Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers
EP2380991A1 (en) 2010-04-20 2011-10-26 Universitätsklinikum Hamburg-Eppendorf Method of determining the metastatic potential of a tumor
EP2975399B1 (en) * 2010-09-15 2022-05-11 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
US9926604B2 (en) 2011-10-14 2018-03-27 The Regents Of The University Of California Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same
PL2872646T3 (pl) * 2012-07-12 2018-03-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3164069B1 (en) * 2014-07-03 2020-09-16 University Of Virginia Patent Foundation Systems and methods for identifying and profiling muscle patterns
US20170298443A1 (en) * 2014-09-25 2017-10-19 Moffitt Genetics Corporation Prognostic tumor biomarkers
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
JP6489900B2 (ja) * 2015-03-30 2019-03-27 株式会社ジャパンディスプレイ 入力装置及び表示装置
TWI806815B (zh) 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之ｇａｔａ３相關之腫瘤特異性新抗原
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
GB201908565D0 (en) * 2019-06-14 2019-07-31 Cray Innovation Ab Method of stratifying subjects into sub-groups for therapeutic treatment
CN114540504B (zh) * 2022-04-27 2022-07-08 广州万德基因医学科技有限公司 用于预测肺鳞癌患者免疫疗效的标志物组及系统

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
ES2255248T3 (es) 1998-02-05 2006-06-16 Glaxosmithkline Biologicals S.A. Derivados de antigenos asociados a tumor de la familia mage, y secuencias de acidos nucleicos que los codifican, usados para la preparacion de proteinas de fusion y de composiciones para vacunas.
ATE315405T1 (de) 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
DE60044665D1 (de) 1999-01-29 2010-08-26 Corixa Corp Her2/neu fusionsproteine
PT1165778E (pt) 1999-03-11 2007-01-31 Glaxosmithkline Biolog Sa Utilizações de polinucleótidos e polipéptidos casb618
CA2370697C (en) 1999-04-19 2012-03-06 Smithkline Beecham Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
ATE487733T1 (de) 2000-02-23 2010-11-15 Glaxosmithkline Biolog Sa Neue verbindungen
AUPR077900A0 (en) * 2000-10-13 2000-11-09 Tvw Telethon Institute For Child Health Research Immunodiagnosis
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
WO2002068614A2 (en) * 2001-02-26 2002-09-06 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
WO2002076469A1 (en) * 2001-03-27 2002-10-03 Baylor College Of Medicine A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
JP4424987B2 (ja) * 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
ATE447844T1 (de) 2002-02-04 2009-11-15 Corixa Corp Neue immuneffektor-verbindungen
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
RU2004135541A (ru) 2002-06-11 2005-10-10 ГлаксоСмитКлайн Байолоджикалз с.а. (BE) Иммуногенные композиции
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US20050054496A1 (en) * 2003-02-25 2005-03-10 Harms Robert E. Coated weight plates, dumbbells and method of manufacture
EP1605811A4 (en) * 2003-02-28 2008-06-11 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR BREAST CANCER AND METHODS OF USE
WO2005098037A1 (en) * 2003-03-07 2005-10-20 Arcturus Bioscience, Inc. Breast cancer signatures
EP1608964A4 (en) 2003-03-14 2009-07-15 Peter Maccallum Cancer Inst CREATING AN EXPRESSION PROFILE OF TUMORS
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US7640114B2 (en) * 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells
WO2004111603A2 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005049829A1 (en) 2003-05-30 2005-06-02 Astrazeneca Uk Limited Process
US20050100933A1 (en) * 2003-06-18 2005-05-12 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
ES2378156T3 (es) * 2003-06-27 2012-04-09 International Institute Of Cancer Immunology, Inc. Método para seleccionar pacientes adecuados para vacuna de WT1
EP1980629A3 (en) * 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers
CA2540894A1 (en) * 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
WO2005044999A2 (en) * 2003-11-05 2005-05-19 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
WO2005054496A1 (ja) * 2003-12-02 2005-06-16 Orient Cancer Therapy Co., Ltd. 細胞動態の検査方法
WO2005059543A1 (en) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor h963 (h963)
KR20070003883A (ko) * 2004-02-09 2007-01-05 후소 야쿠힝 고교 가부시끼가이샤 핵산 검출방법 및 그 이용
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
ES2351995T3 (es) * 2004-06-17 2011-02-14 Mannkind Corporation Perfiles de antígenos asociados a tumores en el diagnóstico de cáncer e inmunoterapia.
EP1786465A4 (en) * 2004-07-30 2009-01-21 Univ Oregon Health & Science METHODS FOR DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
WO2006056304A2 (en) * 2004-11-23 2006-06-01 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
CA2589782A1 (en) 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
WO2006073982A2 (en) * 2004-12-30 2006-07-13 Regents Of The University Of California Bispecific molecule comprising ligands for cell-surface protein and t-cell surface protein
WO2006091776A2 (en) 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
WO2006103442A2 (en) 2005-04-01 2006-10-05 Ncc Technology Ventures Pte. Ltd. Materials and methods relating to breast cancer classification
CA2604844A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
WO2006113678A2 (en) * 2005-04-15 2006-10-26 Oncomethylome Sciences, Inc. Methylation markers for diagnosis and treatment of cancers
US20090186024A1 (en) 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
US20080199850A1 (en) * 2005-10-11 2008-08-21 Merck Patent Gmbh Egfr Dependent Modulation of Chemokine Expression and Influence on Therapy and Diagnosis of Tumors and Side Effects Thereof
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Also Published As

Publication number Publication date
EP2392675A1 (en) 2011-12-07
EP2390354A1 (en) 2011-11-30
ES2539042T3 (es) 2015-06-25
EP2390355A1 (en) 2011-11-30
WO2007140958A3 (en) 2008-07-03
EP2390363A1 (en) 2011-11-30
EP2392673A1 (en) 2011-12-07
EP2390356A1 (en) 2011-11-30
EP2390364A1 (en) 2011-11-30
EP2390365A1 (en) 2011-11-30
PE20080742A1 (es) 2008-08-06
EP2392672A1 (en) 2011-12-07
EP2390359A1 (en) 2011-11-30
EP2392671A1 (en) 2011-12-07
MX2008015372A (es) 2009-03-23
TW200817680A (en) 2008-04-16
EP2390353A1 (en) 2011-11-30
CA2653949A1 (en) 2007-12-13
US20100021424A1 (en) 2010-01-28
JP2009538607A (ja) 2009-11-12
EP2258874A1 (en) 2010-12-08
EP2032719A2 (en) 2009-03-11
EP2390358A1 (en) 2011-11-30
EA200802242A1 (ru) 2009-08-28
AU2007256383A1 (en) 2007-12-13
EP2390361A1 (en) 2011-11-30
EP2390362A1 (en) 2011-11-30
CL2007001571A1 (es) 2008-05-16
KR20090017655A (ko) 2009-02-18
EP2390367A1 (en) 2011-11-30
EP2390369A1 (en) 2011-11-30
BRPI0712497A2 (pt) 2012-09-18
EP2390357A1 (en) 2011-11-30
AU2007256383B2 (en) 2013-06-06
WO2007140958A9 (en) 2009-11-26
WO2007140958A2 (en) 2007-12-13
EP2390368A1 (en) 2011-11-30
EP2390366A1 (en) 2011-11-30
EP2258874B1 (en) 2015-03-18
EP2390360A1 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
AR061136A1 (es) Procedimiento
WO2012174256A3 (en) Dna methylation profiles in cancer
WO2010073248A3 (en) Gene expression signature for classification of tissue of origin of tumor samples
WO2005111211A8 (en) Micronas and uses thereof
IN2012DN04944A (es)
EP3839050A3 (en) Non-disruptive gene targeting
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2010081001A3 (en) Recurrent gene fusions in cancer
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
NZ703824A (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
EP3296406A3 (en) Mirna fingerprint in the diagnosis of lung cancer
EP2569453A4 (en) Nucleic Acid ISOLATION METHOD
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2008079269A3 (en) Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
ES2530843T3 (es) Métodos basados en microARN para el diagnóstico de cáncer de páncreas
MX2013003153A (es) Analogos de nucleotidos sustituidos.
WO2007058968A3 (en) Gene expression profiles and methods of use
CA2835730C (en) Molecular markers in prostate cancer
ATE461294T1 (de) Brustkrebsdiagnoseverfahren
SG179129A1 (en) Method for identifying whether a patient will be responder or not to immunotherapy
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
MX2013004747A (es) Marcadores de gen de sangre periferica para el diagnostico temprano de la enfermedad de parkinson.
WO2009121878A3 (en) In vitro diagnostic method for the diagnosis of somatic and ovarian cancers
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载